UBS Group AG reduced its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 40.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,950 shares of the biotechnology company’s stock after selling 305,929 shares during the period. UBS Group AG owned about 0.29% of Ironwood Pharmaceuticals worth $4,570,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $29,000. Amundi Pioneer Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $63,000. AJO LP purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $89,000. Neo Ivy Capital Management purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $134,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Ironwood Pharmaceuticals by 22.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,320 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,868 shares in the last quarter.

IRWD stock opened at $11.85 on Friday. Ironwood Pharmaceuticals, Inc. has a 52-week low of $7.91 and a 52-week high of $14.10. The stock’s fifty day simple moving average is $10.27 and its 200-day simple moving average is $11.55. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 22.36 and a beta of 1.49.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 96.13% and a net margin of 19.14%. The business had revenue of $79.94 million for the quarter, compared to analyst estimates of $78.62 million. During the same quarter last year, the business earned ($0.26) EPS. Ironwood Pharmaceuticals’s revenue for the quarter was up 16.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.4 EPS for the current year.

Several research firms recently weighed in on IRWD. Wells Fargo & Co dropped their price objective on Ironwood Pharmaceuticals from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Zacks Investment Research downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating and set a $11.00 price target for the company. in a research report on Thursday, March 26th. Credit Suisse Group reissued a “hold” rating and set a $12.00 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday, May 7th. TheStreet downgraded Ironwood Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Monday, May 11th. Finally, Morgan Stanley dropped their price target on Ironwood Pharmaceuticals from $12.00 to $11.00 and set an “equal weight” rating for the company in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Further Reading: Limitations of the P/E Growth ratio

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.